Literature DB >> 12354469

Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study.

Kjell Bergfeldt1, Bosse Rydh, Fredrik Granath, Henrik Grönberg, Lukman Thalib, Hans-Olov Adami, Per Hall.   

Abstract

BACKGROUND: Patients with breast cancer who have mutations in the high penetrance genes BRCA1 and BRCA2, have an increased risk of ovarian cancer. Because these mutations are rare, easily obtained information such as age and family history of breast or ovarian cancer might be preferable for assessment of ovarian cancer risk in clinical practice.
METHODS: We linked data from the Swedish Cancer Register to the Swedish Generation Register and generated a cohort of 30552 breast-cancer patients born after 1931, with information on breast and ovarian cancer diagnosis from 146117 first-degree relatives. Standardised incidence ratios (SIRs) with 95% CIs were calculated with nationwide rates of ovarian cancer, adjusted for age and calendar year.
FINDINGS: During a mean follow-up of 6 years, 122 incident ovarian cancers were identified in the cohort, yielding an overall SIR of 2.0 (95% CI 1.6-2.4). The risk was higher in breast-cancer patients diagnosed before the age of 40 years, with a family history of breast cancer (5.6; 1.8-13.1) or ovarian cancer (17.0; 3.5-50.0). A consistently increased risk was noted in patients with a relative who was diagnosed before the age of 50 years, with either breast or ovarian cancer. Women with a family history of ovarian cancer have an almost 10% risk of developing ovarian cancer before the age of 70.
INTERPRETATION: In young women with breast cancer, the risk of ovarian cancer is greatly raised when a family history of breast or ovarian cancer is present. Close medical surveillance, and perhaps even prophylactic oophorectomy, might be justified in high-risk groups.

Entities:  

Mesh:

Year:  2002        PMID: 12354469     DOI: 10.1016/S0140-6736(02)11023-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  11 in total

Review 1.  Novel agents for chemoprevention, screening methods, and sampling issues.

Authors:  Mary Jo Fackler; Ella Evron; Seema A Khan; Saraswati Sukumar
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

2.  Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.

Authors:  Zakaria Einbeigi; Annika Bergman; Jeanne M Meis-Kindblom; Anna Flodin; Cecilia Bjursell; Tommy Martinsson; Lars-Gunnar Kindblom; Jan Wahlström; Arne Wallgren; Margareta Nordling; Per Karlsson
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

3.  A breast cancer prognostic signature predicts clinical outcomes in multiple tumor types.

Authors:  Ying-Wooi Wan; Yong Qian; Shruti Rathnagiriswaran; Vincent Castranova; Nancy Lan Guo
Journal:  Oncol Rep       Date:  2010-08       Impact factor: 3.906

4.  Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status.

Authors:  D G R Evans; A Moran; R Hartley; J Dawson; B Bulman; F Knox; A Howell; F Lalloo
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

Review 5.  Clinical epidemiology of epithelial ovarian cancer in the UK.

Authors:  Konstantinos Doufekas; Adeola Olaitan
Journal:  Int J Womens Health       Date:  2014-05-23

6.  Metastatic ovarian carcinoma in breast cancer patients during risk-reducing salpingo-oophorectomy: Report of two cases.

Authors:  Prafulla Shakya; Anu Bajracharya; Suraj Shrestha; Sanjeev Kharel; Rubina Maharjan; Aagon Krishna Shrestha
Journal:  Ann Med Surg (Lond)       Date:  2021-12-06

7.  Diagnostic Accuracy of Whole-Body Computed Tomography for Incidental Ovarian Tumors in Patients with Prior Breast Cancer.

Authors:  Pei-Ching Huang; Ren-Chin Wu; Yu-Hsiang Juan; Hui-Yu Ho; Yung-Chang Lin; Yi-Ting Huang; Shu-Hang Ng; Chyong-Huey Lai; Angel Chao; Gigin Lin
Journal:  Diagnostics (Basel)       Date:  2022-01-29

8.  Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.

Authors:  Bernadette A M Heemskerk-Gerritsen; Cecile T M Brekelmans; Marian B E Menke-Pluymers; Albert N van Geel; Madeleine M A Tilanus-Linthorst; Carina C M Bartels; Murly Tan; Hanne E J Meijers-Heijboer; Jan G M Klijn; Caroline Seynaeve
Journal:  Ann Surg Oncol       Date:  2007-05-31       Impact factor: 5.344

9.  Long disease-free survival (48 months) in a breast cancer patient with ovarian and pelvic metastasis-a case report.

Authors:  Yu Feng; Xia Zhao; Shuzhen Lv; Bingjun Xiong; Yanping Li; Man Zhang
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

10.  Clinical characteristics and survival outcomes of patients with both primary breast cancer and primary ovarian cancer.

Authors:  Chang Chen; Yali Xu; Xin Huang; Feng Mao; Songjie Shen; Ying Xu; Qiang Sun
Journal:  Medicine (Baltimore)       Date:  2020-08-07       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.